PittsburghV1, PascalFrancis, Corpus, bibRecord, 001044

Pulmonary Hypertension in Chronic Lung Diseases

Identifieur interne : 001044 ( PascalFrancis/Corpus ); précédent : 001043; suivant : 001045

Pulmonary Hypertension in Chronic Lung Diseases

Auteurs : Werner Seeger ; Yochai Adir ; Joan Albert Barbera ; Hunter Champion ; John Gerard Coghlan ; Vincent Cottin ; Teresa De Marco ; Nazzareno Galie ; Stefano Ghio ; Simon Gibbs ; Fernando J. Martinez ; Marc J. Semigran ; Gerald Simonneau ; Athol U. Wells ; Jean-Luc Vachiery

Source :

Journal of the American College of Cardiology [ 0735-1097 ] ; 2013.

RBID : Pascal:14-0036895

Descripteurs français

Pascal (Inist)
- Hypertension artérielle pulmonaire, Pathologie des poumons, Maladie chronique, Pathologie de l'appareil circulatoire, Chronique, Appareil circulatoire, Cardiologie.

English descriptors

KwdEn :
- Cardiology, Cardiovascular disease, Chronic, Chronic disease, Circulatory system, Lung disease, Pulmonary hypertension.

Abstract

Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse prognosis. Patients with combined pulmonary fibrosis and emphysema (CPFE) are particularly prone to the development of PH. Echocardiography and right heart catheterization are the principal modalities for the diagnosis of COPD and DPLD. For discrimination between group 1PH patients with concomitant respiratory abnormalities and group 3 PH patients (PH caused by lung disease), patients should be transferred to a center with expertise in both PH and lung diseases for comprehensive evaluation. The task force encompassing the authors of this article provided criteria for this discrimination and suggested using the following definitions for group 3 patients, as exemplified for COPD, IPF, and CPFE: COPD/IPF/CPFE without PH (mean pulmonary artery pressure [mPAP] <25 mm Hg); COPD/IPF/CPFE with PH (mPAP ≥25 mm Hg); PH-COPD, PH-IPF, and PH-CPFE); COPD/IPF/CPFE with severe PH (mPAP ≥35 mm Hg or mPAP ≥25 mm Hg with low cardiac index [Cl <2.0l/min/m²]; severe PH-COPD, severe PH-IPF, and severe PH-CPFE). The "severe PH group" includes only a minority of chronic lung disease patients who are suspected of having strong general vascular abnormalities (remodeling) accompanying the parenchymal disease and with evidence of an exhausted circulatory reserve rather than an exhausted ventilatory reserve underlyingthe limitation of exercise capacity. Exertional dyspnea disproportionate to pulmonary function tests, low carbon monoxide diffusion capacity, and rapid decline of arterial oxygenation upon exercise are typical clinical features of this subgroup with poor prognosis. Studies evaluating the effect of pulmonary arterial hypertension drugs currently not approved for group 3 PH patients should focus on this severe PH group, and for the time being, these patients should be transferred to expert centers for individualized patient care.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0735-1097`
A02	`01`			`@0 JACCDI`
A03		`1`		`@0 J. Am. Coll. Cardiol.`
A05				`@2 62`
A06				`@2 25 @3 SUPD`
A08	`01`	`1`	`ENG`	`@1 Pulmonary Hypertension in Chronic Lung Diseases`
A09	`01`	`1`	`ENG`	`@1 Updates in Pulmonary Hypertension: Proceedings of the 5th World Symposium on Pulmonary Hypertension`
A11	`01`	`1`		`@1 SEEGER (Werner)`
A11	`02`	`1`		`@1 ADIR (Yochai)`
A11	`03`	`1`		`@1 BARBERA (Joan Albert)`
A11	`04`	`1`		`@1 CHAMPION (Hunter)`
A11	`05`	`1`		`@1 COGHLAN (John Gerard)`
A11	`06`	`1`		`@1 COTTIN (Vincent)`
A11	`07`	`1`		`@1 DE MARCO (Teresa)`
A11	`08`	`1`		`@1 GALIE (Nazzareno)`
A11	`09`	`1`		`@1 GHIO (Stefano)`
A11	`10`	`1`		`@1 GIBBS (Simon)`
A11	`11`	`1`		`@1 MARTINEZ (Fernando J.)`
A11	`12`	`1`		`@1 SEMIGRAN (Marc J.)`
A11	`13`	`1`		`@1 SIMONNEAU (Gerald)`
A11	`14`	`1`		`@1 WELLS (Athol U.)`
A11	`15`	`1`		`@1 VACHIERY (Jean-Luc)`
A12	`01`	`1`		`@1 GALIE (Nazzareno) @9 ed.`
A12	`02`	`1`		`@1 SIMONNEAU (Gerald) @9 ed.`
A14	`01`			`@1 University of Giessen and Marburg Lung Center (UGMLC) @3 DEU @Z 1 aut.`
A14	`02`			`@1 German Center for Lung Research, Max-Planck Institute for Heart and Lung Research @2 Giessen/Bad Nauheim @3 DEU @Z 1 aut.`
A14	`03`			`@1 Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine, The Technion, Institute of Technology @2 Haifa @3 ISR @Z 2 aut.`
A14	`04`			`@1 Hospital Clínic-IDIBAPS, University of Barcelona, Network Center of Biomedical Research on Respiratory Diseases @2 Barcelona @3 ESP @Z 3 aut.`
A14	`05`			`@1 UPMC Montefiore Hospital @2 Pittsburgh, Pennsylvania @3 USA @Z 4 aut.`
A14	`06`			`@1 Department of Cardiology, Royal Free Hospital @2 London @3 GBR @Z 5 aut.`
A14	`07`			`@1 Hospices civils de Lyon, Louis Pradel Hospital, Department of Respiratory Diseases, National Reference Center for Rare Pulmonary Diseases, Regional Competence Center for Severe Pulmonary Arterial Hypertension, Claude Bernard University Lyon 1, INRA @2 Lyon @3 FRA @Z 6 aut.`
A14	`08`			`@1 University of California San Francisco @2 San Francisco, California @3 USA @Z 7 aut.`
A14	`09`			`@1 Department of Experimental, Diagnostic, and Specialty Medicine, DIMES, Bologna University Hospital @2 Bologna @3 ITA @Z 8 aut.`
A14	`10`			`@1 Divisione di Cardiologia, Fondazione IRCCS Policlinico San Matteo @2 Pavia @3 ITA @Z 9 aut.`
A14	`11`			`@1 National Heart and Lung Institute, Imperial College London, and Department of Cardiology, National Pulmonary Hypertension Service, Hammersmith Hospital @2 London @3 GBR @Z 10 aut.`
A14	`12`			`@1 Division of Pulmonary and Critical Care, University of Michigan Medical Center @2 Ann Arbor, Michigan @3 USA @Z 11 aut.`
A14	`13`			`@1 Heart Failure and Cardiac Transplantation Center, Massachusetts General Hospital @2 Boston, Massachusetts @3 USA @Z 12 aut.`
A14	`14`			`@1 Centre National de Reference des Maladies Vasculaires Pulmonaires, Université Paris-Sud, Hôpital Antoine Béclère @2 Clamart @3 FRA @Z 13 aut.`
A14	`15`			`@1 Royal Brompton and Harefield NHS Foundation Trust @2 London @3 GBR @Z 14 aut.`
A14	`16`			`@1 Department of Cardiology, Hôpital Erasme, Université Libre de Bruxelles @2 Brussels @3 BEL @Z 15 aut.`
A15	`01`			`@1 Department of Experimental, Diagnostic and Specialty Medicine-DIMES @2 Bologna @3 ITA @Z 1 aut.`
A15	`02`			`@1 Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Universitaire de Bicêtre, Université Paris-Sud, Laboratoire d'excellence en Recherche sur le Médicament et Innovation Thérapeutique, INSERM, Unité 999 @2 Le Kremlin-Bicêtre, Paris @3 FRA @Z 2 aut.`
A20				`@2 D109-D116`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20098 @5 354000500747320120`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 82 ref.`
A47	`01`	`1`		`@0 14-0036895`
A60				`@1 P @2 C`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of the American College of Cardiology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse prognosis. Patients with combined pulmonary fibrosis and emphysema (CPFE) are particularly prone to the development of PH. Echocardiography and right heart catheterization are the principal modalities for the diagnosis of COPD and DPLD. For discrimination between group 1PH patients with concomitant respiratory abnormalities and group 3 PH patients (PH caused by lung disease), patients should be transferred to a center with expertise in both PH and lung diseases for comprehensive evaluation. The task force encompassing the authors of this article provided criteria for this discrimination and suggested using the following definitions for group 3 patients, as exemplified for COPD, IPF, and CPFE: COPD/IPF/CPFE without PH (mean pulmonary artery pressure [mPAP] <25 mm Hg); COPD/IPF/CPFE with PH (mPAP ≥25 mm Hg); PH-COPD, PH-IPF, and PH-CPFE); COPD/IPF/CPFE with severe PH (mPAP ≥35 mm Hg or mPAP ≥25 mm Hg with low cardiac index [Cl <2.0l/min/m²]; severe PH-COPD, severe PH-IPF, and severe PH-CPFE). The "severe PH group" includes only a minority of chronic lung disease patients who are suspected of having strong general vascular abnormalities (remodeling) accompanying the parenchymal disease and with evidence of an exhausted circulatory reserve rather than an exhausted ventilatory reserve underlyingthe limitation of exercise capacity. Exertional dyspnea disproportionate to pulmonary function tests, low carbon monoxide diffusion capacity, and rapid decline of arterial oxygenation upon exercise are typical clinical features of this subgroup with poor prognosis. Studies evaluating the effect of pulmonary arterial hypertension drugs currently not approved for group 3 PH patients should focus on this severe PH group, and for the time being, these patients should be transferred to expert centers for individualized patient care.
C02	`01`	`X`		`@0 002B12A`
C02	`02`	`X`		`@0 002B11C`
C03	`01`	`X`	`FRE`	`@0 Hypertension artérielle pulmonaire @5 01`
C03	`01`	`X`	`ENG`	`@0 Pulmonary hypertension @5 01`
C03	`01`	`X`	`SPA`	`@0 Hipertensión arterial pulmonar @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie des poumons @5 02`
C03	`02`	`X`	`ENG`	`@0 Lung disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Pulmón patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Maladie chronique @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Chronic disease @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Enfermedad crónica @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 04`
C03	`04`	`X`	`ENG`	`@0 Cardiovascular disease @5 04`
C03	`04`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 04`
C03	`05`	`X`	`FRE`	`@0 Chronique @5 09`
C03	`05`	`X`	`ENG`	`@0 Chronic @5 09`
C03	`05`	`X`	`SPA`	`@0 Crónico @5 09`
C03	`06`	`X`	`FRE`	`@0 Appareil circulatoire @5 10`
C03	`06`	`X`	`ENG`	`@0 Circulatory system @5 10`
C03	`06`	`X`	`SPA`	`@0 Aparato circulatorio @5 10`
C03	`07`	`X`	`FRE`	`@0 Cardiologie @5 11`
C03	`07`	`X`	`ENG`	`@0 Cardiology @5 11`
C03	`07`	`X`	`SPA`	`@0 Cardiología @5 11`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil respiratoire @5 37`
C07	`01`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
N21				`@1 041`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

A30	`01`	`1`	`ENG`	`@1 WSPH World Symposium on Pulmonary Hypertension @2 5 @3 Nice FRA @4 2013-02-27`

Format Inist (serveur)

NO :	PASCAL 14-0036895 INIST
ET :	Pulmonary Hypertension in Chronic Lung Diseases
AU :	SEEGER (Werner); ADIR (Yochai); BARBERA (Joan Albert); CHAMPION (Hunter); COGHLAN (John Gerard); COTTIN (Vincent); DE MARCO (Teresa); GALIE (Nazzareno); GHIO (Stefano); GIBBS (Simon); MARTINEZ (Fernando J.); SEMIGRAN (Marc J.); SIMONNEAU (Gerald); WELLS (Athol U.); VACHIERY (Jean-Luc); GALIE (Nazzareno); SIMONNEAU (Gerald)
AF :	University of Giessen and Marburg Lung Center (UGMLC)/Allemagne (1 aut.); German Center for Lung Research, Max-Planck Institute for Heart and Lung Research/Giessen/Bad Nauheim/Allemagne (1 aut.); Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine, The Technion, Institute of Technology/Haifa/Israël (2 aut.); Hospital Clínic-IDIBAPS, University of Barcelona, Network Center of Biomedical Research on Respiratory Diseases/Barcelona/Espagne (3 aut.); UPMC Montefiore Hospital/Pittsburgh, Pennsylvania/Etats-Unis (4 aut.); Department of Cardiology, Royal Free Hospital/London/Royaume-Uni (5 aut.); Hospices civils de Lyon, Louis Pradel Hospital, Department of Respiratory Diseases, National Reference Center for Rare Pulmonary Diseases, Regional Competence Center for Severe Pulmonary Arterial Hypertension, Claude Bernard University Lyon 1, INRA/Lyon/France (6 aut.); University of California San Francisco/San Francisco, California/Etats-Unis (7 aut.); Department of Experimental, Diagnostic, and Specialty Medicine, DIMES, Bologna University Hospital/Bologna/Italie (8 aut.); Divisione di Cardiologia, Fondazione IRCCS Policlinico San Matteo/Pavia/Italie (9 aut.); National Heart and Lung Institute, Imperial College London, and Department of Cardiology, National Pulmonary Hypertension Service, Hammersmith Hospital/London/Royaume-Uni (10 aut.); Division of Pulmonary and Critical Care, University of Michigan Medical Center/Ann Arbor, Michigan/Etats-Unis (11 aut.); Heart Failure and Cardiac Transplantation Center, Massachusetts General Hospital/Boston, Massachusetts/Etats-Unis (12 aut.); Centre National de Reference des Maladies Vasculaires Pulmonaires, Université Paris-Sud, Hôpital Antoine Béclère/Clamart/France (13 aut.); Royal Brompton and Harefield NHS Foundation Trust/London/Royaume-Uni (14 aut.); Department of Cardiology, Hôpital Erasme, Université Libre de Bruxelles/Brussels/Belgique (15 aut.); Department of Experimental, Diagnostic and Specialty Medicine-DIMES/Bologna/Italie (1 aut.); Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Universitaire de Bicêtre, Université Paris-Sud, Laboratoire d'excellence en Recherche sur le Médicament et Innovation Thérapeutique, INSERM, Unité 999/Le Kremlin-Bicêtre, Paris/France (2 aut.)
DT :	Publication en série; Congrès; Niveau analytique
SO :	Journal of the American College of Cardiology; ISSN 0735-1097; Coden JACCDI; Etats-Unis; Da. 2013; Vol. 62; No. 25 SUPD; D109-D116; Bibl. 82 ref.
LA :	Anglais
EA :	Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse prognosis. Patients with combined pulmonary fibrosis and emphysema (CPFE) are particularly prone to the development of PH. Echocardiography and right heart catheterization are the principal modalities for the diagnosis of COPD and DPLD. For discrimination between group 1PH patients with concomitant respiratory abnormalities and group 3 PH patients (PH caused by lung disease), patients should be transferred to a center with expertise in both PH and lung diseases for comprehensive evaluation. The task force encompassing the authors of this article provided criteria for this discrimination and suggested using the following definitions for group 3 patients, as exemplified for COPD, IPF, and CPFE: COPD/IPF/CPFE without PH (mean pulmonary artery pressure [mPAP] <25 mm Hg); COPD/IPF/CPFE with PH (mPAP ≥25 mm Hg); PH-COPD, PH-IPF, and PH-CPFE); COPD/IPF/CPFE with severe PH (mPAP ≥35 mm Hg or mPAP ≥25 mm Hg with low cardiac index [Cl <2.0l/min/m²]; severe PH-COPD, severe PH-IPF, and severe PH-CPFE). The "severe PH group" includes only a minority of chronic lung disease patients who are suspected of having strong general vascular abnormalities (remodeling) accompanying the parenchymal disease and with evidence of an exhausted circulatory reserve rather than an exhausted ventilatory reserve underlyingthe limitation of exercise capacity. Exertional dyspnea disproportionate to pulmonary function tests, low carbon monoxide diffusion capacity, and rapid decline of arterial oxygenation upon exercise are typical clinical features of this subgroup with poor prognosis. Studies evaluating the effect of pulmonary arterial hypertension drugs currently not approved for group 3 PH patients should focus on this severe PH group, and for the time being, these patients should be transferred to expert centers for individualized patient care.
CC :	002B12A; 002B11C
FD :	Hypertension artérielle pulmonaire; Pathologie des poumons; Maladie chronique; Pathologie de l'appareil circulatoire; Chronique; Appareil circulatoire; Cardiologie
FG :	Pathologie de l'appareil respiratoire
ED :	Pulmonary hypertension; Lung disease; Chronic disease; Cardiovascular disease; Chronic; Circulatory system; Cardiology
EG :	Respiratory disease
SD :	Hipertensión arterial pulmonar; Pulmón patología; Enfermedad crónica; Aparato circulatorio patología; Crónico; Aparato circulatorio; Cardiología
LO :	INIST-20098.354000500747320120
ID :	14-0036895

Links to Exploration step

Pascal:14-0036895

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pulmonary Hypertension in Chronic Lung Diseases</title>
<author><name sortKey="Seeger, Werner" sort="Seeger, Werner" uniqKey="Seeger W" first="Werner" last="Seeger">Werner Seeger</name>
<affiliation><inist:fA14 i1="01"><s1>University of Giessen and Marburg Lung Center (UGMLC)</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Lung Research, Max-Planck Institute for Heart and Lung Research</s1>
<s2>Giessen/Bad Nauheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Adir, Yochai" sort="Adir, Yochai" uniqKey="Adir Y" first="Yochai" last="Adir">Yochai Adir</name>
<affiliation><inist:fA14 i1="03"><s1>Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine, The Technion, Institute of Technology</s1>
<s2>Haifa</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Barbera, Joan Albert" sort="Barbera, Joan Albert" uniqKey="Barbera J" first="Joan Albert" last="Barbera">Joan Albert Barbera</name>
<affiliation><inist:fA14 i1="04"><s1>Hospital Clínic-IDIBAPS, University of Barcelona, Network Center of Biomedical Research on Respiratory Diseases</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Champion, Hunter" sort="Champion, Hunter" uniqKey="Champion H" first="Hunter" last="Champion">Hunter Champion</name>
<affiliation><inist:fA14 i1="05"><s1>UPMC Montefiore Hospital</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coghlan, John Gerard" sort="Coghlan, John Gerard" uniqKey="Coghlan J" first="John Gerard" last="Coghlan">John Gerard Coghlan</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Cardiology, Royal Free Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cottin, Vincent" sort="Cottin, Vincent" uniqKey="Cottin V" first="Vincent" last="Cottin">Vincent Cottin</name>
<affiliation><inist:fA14 i1="07"><s1>Hospices civils de Lyon, Louis Pradel Hospital, Department of Respiratory Diseases, National Reference Center for Rare Pulmonary Diseases, Regional Competence Center for Severe Pulmonary Arterial Hypertension, Claude Bernard University Lyon 1, INRA</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Marco, Teresa" sort="De Marco, Teresa" uniqKey="De Marco T" first="Teresa" last="De Marco">Teresa De Marco</name>
<affiliation><inist:fA14 i1="08"><s1>University of California San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galie">Nazzareno Galie</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Experimental, Diagnostic, and Specialty Medicine, DIMES, Bologna University Hospital</s1>
<s2>Bologna</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ghio, Stefano" sort="Ghio, Stefano" uniqKey="Ghio S" first="Stefano" last="Ghio">Stefano Ghio</name>
<affiliation><inist:fA14 i1="10"><s1>Divisione di Cardiologia, Fondazione IRCCS Policlinico San Matteo</s1>
<s2>Pavia</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gibbs, Simon" sort="Gibbs, Simon" uniqKey="Gibbs S" first="Simon" last="Gibbs">Simon Gibbs</name>
<affiliation><inist:fA14 i1="11"><s1>National Heart and Lung Institute, Imperial College London, and Department of Cardiology, National Pulmonary Hypertension Service, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez, Fernando J" sort="Martinez, Fernando J" uniqKey="Martinez F" first="Fernando J." last="Martinez">Fernando J. Martinez</name>
<affiliation><inist:fA14 i1="12"><s1>Division of Pulmonary and Critical Care, University of Michigan Medical Center</s1>
<s2>Ann Arbor, Michigan</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Semigran, Marc J" sort="Semigran, Marc J" uniqKey="Semigran M" first="Marc J." last="Semigran">Marc J. Semigran</name>
<affiliation><inist:fA14 i1="13"><s1>Heart Failure and Cardiac Transplantation Center, Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Simonneau, Gerald" sort="Simonneau, Gerald" uniqKey="Simonneau G" first="Gerald" last="Simonneau">Gerald Simonneau</name>
<affiliation><inist:fA14 i1="14"><s1>Centre National de Reference des Maladies Vasculaires Pulmonaires, Université Paris-Sud, Hôpital Antoine Béclère</s1>
<s2>Clamart</s2>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wells, Athol U" sort="Wells, Athol U" uniqKey="Wells A" first="Athol U." last="Wells">Athol U. Wells</name>
<affiliation><inist:fA14 i1="15"><s1>Royal Brompton and Harefield NHS Foundation Trust</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vachiery, Jean Luc" sort="Vachiery, Jean Luc" uniqKey="Vachiery J" first="Jean-Luc" last="Vachiery">Jean-Luc Vachiery</name>
<affiliation><inist:fA14 i1="16"><s1>Department of Cardiology, Hôpital Erasme, Université Libre de Bruxelles</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0036895</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 14-0036895 INIST</idno>
<idno type="RBID">Pascal:14-0036895</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001044</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Pulmonary Hypertension in Chronic Lung Diseases</title>
<author><name sortKey="Seeger, Werner" sort="Seeger, Werner" uniqKey="Seeger W" first="Werner" last="Seeger">Werner Seeger</name>
<affiliation><inist:fA14 i1="01"><s1>University of Giessen and Marburg Lung Center (UGMLC)</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Lung Research, Max-Planck Institute for Heart and Lung Research</s1>
<s2>Giessen/Bad Nauheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Adir, Yochai" sort="Adir, Yochai" uniqKey="Adir Y" first="Yochai" last="Adir">Yochai Adir</name>
<affiliation><inist:fA14 i1="03"><s1>Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine, The Technion, Institute of Technology</s1>
<s2>Haifa</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Barbera, Joan Albert" sort="Barbera, Joan Albert" uniqKey="Barbera J" first="Joan Albert" last="Barbera">Joan Albert Barbera</name>
<affiliation><inist:fA14 i1="04"><s1>Hospital Clínic-IDIBAPS, University of Barcelona, Network Center of Biomedical Research on Respiratory Diseases</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Champion, Hunter" sort="Champion, Hunter" uniqKey="Champion H" first="Hunter" last="Champion">Hunter Champion</name>
<affiliation><inist:fA14 i1="05"><s1>UPMC Montefiore Hospital</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coghlan, John Gerard" sort="Coghlan, John Gerard" uniqKey="Coghlan J" first="John Gerard" last="Coghlan">John Gerard Coghlan</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Cardiology, Royal Free Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cottin, Vincent" sort="Cottin, Vincent" uniqKey="Cottin V" first="Vincent" last="Cottin">Vincent Cottin</name>
<affiliation><inist:fA14 i1="07"><s1>Hospices civils de Lyon, Louis Pradel Hospital, Department of Respiratory Diseases, National Reference Center for Rare Pulmonary Diseases, Regional Competence Center for Severe Pulmonary Arterial Hypertension, Claude Bernard University Lyon 1, INRA</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Marco, Teresa" sort="De Marco, Teresa" uniqKey="De Marco T" first="Teresa" last="De Marco">Teresa De Marco</name>
<affiliation><inist:fA14 i1="08"><s1>University of California San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galie">Nazzareno Galie</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Experimental, Diagnostic, and Specialty Medicine, DIMES, Bologna University Hospital</s1>
<s2>Bologna</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ghio, Stefano" sort="Ghio, Stefano" uniqKey="Ghio S" first="Stefano" last="Ghio">Stefano Ghio</name>
<affiliation><inist:fA14 i1="10"><s1>Divisione di Cardiologia, Fondazione IRCCS Policlinico San Matteo</s1>
<s2>Pavia</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gibbs, Simon" sort="Gibbs, Simon" uniqKey="Gibbs S" first="Simon" last="Gibbs">Simon Gibbs</name>
<affiliation><inist:fA14 i1="11"><s1>National Heart and Lung Institute, Imperial College London, and Department of Cardiology, National Pulmonary Hypertension Service, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez, Fernando J" sort="Martinez, Fernando J" uniqKey="Martinez F" first="Fernando J." last="Martinez">Fernando J. Martinez</name>
<affiliation><inist:fA14 i1="12"><s1>Division of Pulmonary and Critical Care, University of Michigan Medical Center</s1>
<s2>Ann Arbor, Michigan</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Semigran, Marc J" sort="Semigran, Marc J" uniqKey="Semigran M" first="Marc J." last="Semigran">Marc J. Semigran</name>
<affiliation><inist:fA14 i1="13"><s1>Heart Failure and Cardiac Transplantation Center, Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Simonneau, Gerald" sort="Simonneau, Gerald" uniqKey="Simonneau G" first="Gerald" last="Simonneau">Gerald Simonneau</name>
<affiliation><inist:fA14 i1="14"><s1>Centre National de Reference des Maladies Vasculaires Pulmonaires, Université Paris-Sud, Hôpital Antoine Béclère</s1>
<s2>Clamart</s2>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wells, Athol U" sort="Wells, Athol U" uniqKey="Wells A" first="Athol U." last="Wells">Athol U. Wells</name>
<affiliation><inist:fA14 i1="15"><s1>Royal Brompton and Harefield NHS Foundation Trust</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vachiery, Jean Luc" sort="Vachiery, Jean Luc" uniqKey="Vachiery J" first="Jean-Luc" last="Vachiery">Jean-Luc Vachiery</name>
<affiliation><inist:fA14 i1="16"><s1>Department of Cardiology, Hôpital Erasme, Université Libre de Bruxelles</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of the American College of Cardiology</title>
<title level="j" type="abbreviated">J. Am. Coll. Cardiol.</title>
<idno type="ISSN">0735-1097</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of the American College of Cardiology</title>
<title level="j" type="abbreviated">J. Am. Coll. Cardiol.</title>
<idno type="ISSN">0735-1097</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cardiology</term>
<term>Cardiovascular disease</term>
<term>Chronic</term>
<term>Chronic disease</term>
<term>Circulatory system</term>
<term>Lung disease</term>
<term>Pulmonary hypertension</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Hypertension artérielle pulmonaire</term>
<term>Pathologie des poumons</term>
<term>Maladie chronique</term>
<term>Pathologie de l'appareil circulatoire</term>
<term>Chronique</term>
<term>Appareil circulatoire</term>
<term>Cardiologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse prognosis. Patients with combined pulmonary fibrosis and emphysema (CPFE) are particularly prone to the development of PH. Echocardiography and right heart catheterization are the principal modalities for the diagnosis of COPD and DPLD. For discrimination between group 1PH patients with concomitant respiratory abnormalities and group 3 PH patients (PH caused by lung disease), patients should be transferred to a center with expertise in both PH and lung diseases for comprehensive evaluation. The task force encompassing the authors of this article provided criteria for this discrimination and suggested using the following definitions for group 3 patients, as exemplified for COPD, IPF, and CPFE: COPD/IPF/CPFE without PH (mean pulmonary artery pressure [mPAP] <25 mm Hg); COPD/IPF/CPFE with PH (mPAP ≥25 mm Hg); PH-COPD, PH-IPF, and PH-CPFE); COPD/IPF/CPFE with severe PH (mPAP ≥35 mm Hg or mPAP ≥25 mm Hg with low cardiac index [Cl <2.0l/min/m<sup>2</sup>
]; severe PH-COPD, severe PH-IPF, and severe PH-CPFE). The "severe PH group" includes only a minority of chronic lung disease patients who are suspected of having strong general vascular abnormalities (remodeling) accompanying the parenchymal disease and with evidence of an exhausted circulatory reserve rather than an exhausted ventilatory reserve underlyingthe limitation of exercise capacity. Exertional dyspnea disproportionate to pulmonary function tests, low carbon monoxide diffusion capacity, and rapid decline of arterial oxygenation upon exercise are typical clinical features of this subgroup with poor prognosis. Studies evaluating the effect of pulmonary arterial hypertension drugs currently not approved for group 3 PH patients should focus on this severe PH group, and for the time being, these patients should be transferred to expert centers for individualized patient care.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0735-1097</s0>
</fA01>
<fA02 i1="01"><s0>JACCDI</s0>
</fA02>
<fA03 i2="1"><s0>J. Am. Coll. Cardiol.</s0>
</fA03>
<fA05><s2>62</s2>
</fA05>
<fA06><s2>25</s2>
<s3>SUPD</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Pulmonary Hypertension in Chronic Lung Diseases</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Updates in Pulmonary Hypertension: Proceedings of the 5th World Symposium on Pulmonary Hypertension</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>SEEGER (Werner)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ADIR (Yochai)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BARBERA (Joan Albert)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CHAMPION (Hunter)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>COGHLAN (John Gerard)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>COTTIN (Vincent)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DE MARCO (Teresa)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GALIE (Nazzareno)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>GHIO (Stefano)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>GIBBS (Simon)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>MARTINEZ (Fernando J.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>SEMIGRAN (Marc J.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>SIMONNEAU (Gerald)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>WELLS (Athol U.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>VACHIERY (Jean-Luc)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>GALIE (Nazzareno)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>SIMONNEAU (Gerald)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>University of Giessen and Marburg Lung Center (UGMLC)</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>German Center for Lung Research, Max-Planck Institute for Heart and Lung Research</s1>
<s2>Giessen/Bad Nauheim</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine, The Technion, Institute of Technology</s1>
<s2>Haifa</s2>
<s3>ISR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Hospital Clínic-IDIBAPS, University of Barcelona, Network Center of Biomedical Research on Respiratory Diseases</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>UPMC Montefiore Hospital</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Cardiology, Royal Free Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Hospices civils de Lyon, Louis Pradel Hospital, Department of Respiratory Diseases, National Reference Center for Rare Pulmonary Diseases, Regional Competence Center for Severe Pulmonary Arterial Hypertension, Claude Bernard University Lyon 1, INRA</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>University of California San Francisco</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Experimental, Diagnostic, and Specialty Medicine, DIMES, Bologna University Hospital</s1>
<s2>Bologna</s2>
<s3>ITA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Divisione di Cardiologia, Fondazione IRCCS Policlinico San Matteo</s1>
<s2>Pavia</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>National Heart and Lung Institute, Imperial College London, and Department of Cardiology, National Pulmonary Hypertension Service, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Division of Pulmonary and Critical Care, University of Michigan Medical Center</s1>
<s2>Ann Arbor, Michigan</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Heart Failure and Cardiac Transplantation Center, Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Centre National de Reference des Maladies Vasculaires Pulmonaires, Université Paris-Sud, Hôpital Antoine Béclère</s1>
<s2>Clamart</s2>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Royal Brompton and Harefield NHS Foundation Trust</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="16"><s1>Department of Cardiology, Hôpital Erasme, Université Libre de Bruxelles</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Department of Experimental, Diagnostic and Specialty Medicine-DIMES</s1>
<s2>Bologna</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Universitaire de Bicêtre, Université Paris-Sud, Laboratoire d'excellence en Recherche sur le Médicament et Innovation Thérapeutique, INSERM, Unité 999</s1>
<s2>Le Kremlin-Bicêtre, Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s2>D109-D116</s2>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20098</s2>
<s5>354000500747320120</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>82 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0036895</s0>
</fA47>
<fA60><s1>P</s1>
<s2>C</s2>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of the American College of Cardiology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse prognosis. Patients with combined pulmonary fibrosis and emphysema (CPFE) are particularly prone to the development of PH. Echocardiography and right heart catheterization are the principal modalities for the diagnosis of COPD and DPLD. For discrimination between group 1PH patients with concomitant respiratory abnormalities and group 3 PH patients (PH caused by lung disease), patients should be transferred to a center with expertise in both PH and lung diseases for comprehensive evaluation. The task force encompassing the authors of this article provided criteria for this discrimination and suggested using the following definitions for group 3 patients, as exemplified for COPD, IPF, and CPFE: COPD/IPF/CPFE without PH (mean pulmonary artery pressure [mPAP] <25 mm Hg); COPD/IPF/CPFE with PH (mPAP ≥25 mm Hg); PH-COPD, PH-IPF, and PH-CPFE); COPD/IPF/CPFE with severe PH (mPAP ≥35 mm Hg or mPAP ≥25 mm Hg with low cardiac index [Cl <2.0l/min/m<sup>2</sup>
]; severe PH-COPD, severe PH-IPF, and severe PH-CPFE). The "severe PH group" includes only a minority of chronic lung disease patients who are suspected of having strong general vascular abnormalities (remodeling) accompanying the parenchymal disease and with evidence of an exhausted circulatory reserve rather than an exhausted ventilatory reserve underlyingthe limitation of exercise capacity. Exertional dyspnea disproportionate to pulmonary function tests, low carbon monoxide diffusion capacity, and rapid decline of arterial oxygenation upon exercise are typical clinical features of this subgroup with poor prognosis. Studies evaluating the effect of pulmonary arterial hypertension drugs currently not approved for group 3 PH patients should focus on this severe PH group, and for the time being, these patients should be transferred to expert centers for individualized patient care.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B12A</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B11C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Hypertension artérielle pulmonaire</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Pulmonary hypertension</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hipertensión arterial pulmonar</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie des poumons</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Maladie chronique</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chronic disease</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Enfermedad crónica</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chronique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chronic</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Crónico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Appareil circulatoire</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Circulatory system</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Aparato circulatorio</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Cardiologie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cardiology</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Cardiología</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fN21><s1>041</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
<pR><fA30 i1="01" i2="1" l="ENG"><s1>WSPH World Symposium on Pulmonary Hypertension</s1>
<s2>5</s2>
<s3>Nice FRA</s3>
<s4>2013-02-27</s4>
</fA30>
</pR>
</standard>
<server><NO>PASCAL 14-0036895 INIST</NO>
<ET>Pulmonary Hypertension in Chronic Lung Diseases</ET>
<AU>SEEGER (Werner); ADIR (Yochai); BARBERA (Joan Albert); CHAMPION (Hunter); COGHLAN (John Gerard); COTTIN (Vincent); DE MARCO (Teresa); GALIE (Nazzareno); GHIO (Stefano); GIBBS (Simon); MARTINEZ (Fernando J.); SEMIGRAN (Marc J.); SIMONNEAU (Gerald); WELLS (Athol U.); VACHIERY (Jean-Luc); GALIE (Nazzareno); SIMONNEAU (Gerald)</AU>
<AF>University of Giessen and Marburg Lung Center (UGMLC)/Allemagne (1 aut.); German Center for Lung Research, Max-Planck Institute for Heart and Lung Research/Giessen/Bad Nauheim/Allemagne (1 aut.); Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine, The Technion, Institute of Technology/Haifa/Israël (2 aut.); Hospital Clínic-IDIBAPS, University of Barcelona, Network Center of Biomedical Research on Respiratory Diseases/Barcelona/Espagne (3 aut.); UPMC Montefiore Hospital/Pittsburgh, Pennsylvania/Etats-Unis (4 aut.); Department of Cardiology, Royal Free Hospital/London/Royaume-Uni (5 aut.); Hospices civils de Lyon, Louis Pradel Hospital, Department of Respiratory Diseases, National Reference Center for Rare Pulmonary Diseases, Regional Competence Center for Severe Pulmonary Arterial Hypertension, Claude Bernard University Lyon 1, INRA/Lyon/France (6 aut.); University of California San Francisco/San Francisco, California/Etats-Unis (7 aut.); Department of Experimental, Diagnostic, and Specialty Medicine, DIMES, Bologna University Hospital/Bologna/Italie (8 aut.); Divisione di Cardiologia, Fondazione IRCCS Policlinico San Matteo/Pavia/Italie (9 aut.); National Heart and Lung Institute, Imperial College London, and Department of Cardiology, National Pulmonary Hypertension Service, Hammersmith Hospital/London/Royaume-Uni (10 aut.); Division of Pulmonary and Critical Care, University of Michigan Medical Center/Ann Arbor, Michigan/Etats-Unis (11 aut.); Heart Failure and Cardiac Transplantation Center, Massachusetts General Hospital/Boston, Massachusetts/Etats-Unis (12 aut.); Centre National de Reference des Maladies Vasculaires Pulmonaires, Université Paris-Sud, Hôpital Antoine Béclère/Clamart/France (13 aut.); Royal Brompton and Harefield NHS Foundation Trust/London/Royaume-Uni (14 aut.); Department of Cardiology, Hôpital Erasme, Université Libre de Bruxelles/Brussels/Belgique (15 aut.); Department of Experimental, Diagnostic and Specialty Medicine-DIMES/Bologna/Italie (1 aut.); Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Universitaire de Bicêtre, Université Paris-Sud, Laboratoire d'excellence en Recherche sur le Médicament et Innovation Thérapeutique, INSERM, Unité 999/Le Kremlin-Bicêtre, Paris/France (2 aut.)</AF>
<DT>Publication en série; Congrès; Niveau analytique</DT>
<SO>Journal of the American College of Cardiology; ISSN 0735-1097; Coden JACCDI; Etats-Unis; Da. 2013; Vol. 62; No. 25 SUPD; D109-D116; Bibl. 82 ref.</SO>
<LA>Anglais</LA>
<EA>Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse prognosis. Patients with combined pulmonary fibrosis and emphysema (CPFE) are particularly prone to the development of PH. Echocardiography and right heart catheterization are the principal modalities for the diagnosis of COPD and DPLD. For discrimination between group 1PH patients with concomitant respiratory abnormalities and group 3 PH patients (PH caused by lung disease), patients should be transferred to a center with expertise in both PH and lung diseases for comprehensive evaluation. The task force encompassing the authors of this article provided criteria for this discrimination and suggested using the following definitions for group 3 patients, as exemplified for COPD, IPF, and CPFE: COPD/IPF/CPFE without PH (mean pulmonary artery pressure [mPAP] <25 mm Hg); COPD/IPF/CPFE with PH (mPAP ≥25 mm Hg); PH-COPD, PH-IPF, and PH-CPFE); COPD/IPF/CPFE with severe PH (mPAP ≥35 mm Hg or mPAP ≥25 mm Hg with low cardiac index [Cl <2.0l/min/m<sup>2</sup>
]; severe PH-COPD, severe PH-IPF, and severe PH-CPFE). The "severe PH group" includes only a minority of chronic lung disease patients who are suspected of having strong general vascular abnormalities (remodeling) accompanying the parenchymal disease and with evidence of an exhausted circulatory reserve rather than an exhausted ventilatory reserve underlyingthe limitation of exercise capacity. Exertional dyspnea disproportionate to pulmonary function tests, low carbon monoxide diffusion capacity, and rapid decline of arterial oxygenation upon exercise are typical clinical features of this subgroup with poor prognosis. Studies evaluating the effect of pulmonary arterial hypertension drugs currently not approved for group 3 PH patients should focus on this severe PH group, and for the time being, these patients should be transferred to expert centers for individualized patient care.</EA>
<CC>002B12A; 002B11C</CC>
<FD>Hypertension artérielle pulmonaire; Pathologie des poumons; Maladie chronique; Pathologie de l'appareil circulatoire; Chronique; Appareil circulatoire; Cardiologie</FD>
<FG>Pathologie de l'appareil respiratoire</FG>
<ED>Pulmonary hypertension; Lung disease; Chronic disease; Cardiovascular disease; Chronic; Circulatory system; Cardiology</ED>
<EG>Respiratory disease</EG>
<SD>Hipertensión arterial pulmonar; Pulmón patología; Enfermedad crónica; Aparato circulatorio patología; Crónico; Aparato circulatorio; Cardiología</SD>
<LO>INIST-20098.354000500747320120</LO>
<ID>14-0036895</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001044 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001044 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0036895
   |texte=   Pulmonary Hypertension in Chronic Lung Diseases
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Pulmonary Hypertension in Chronic Lung Diseases

Pulmonary Hypertension in Chronic Lung Diseases

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri